|
|||||
|
|
| 糖尿病肾病患者口服降糖药应用进展 | |
| 引用本文： | 汪年松,何俐,程东生. 糖尿病肾病患者口服降糖药应用进展[J]. 中华肾病研究电子杂志, 2016, 5(4): 155-158. DOI: 10.3877/cma.j.issn.2095-3216.2016.04.003 |
| 作者姓名： | 汪年松 何俐 程东生 |
| 作者单位： | 1. 200233 上海交通大学附属第六人民医院肾脏科 |
| 基金项目： | 国家自然基金面上项目(81270824); 国家自然基金青年基金项目(81400735); 上海交通大学医学院转化医学基金(152H2011) |
| 摘 要： | 糖尿病肾病已成为全球终末期肾病的最主要病因之一。严格控制血糖可以有效减少糖尿病肾病发生及疾病进展；然而随着肾功能减退，会出现体内降糖药物蓄积，增加药物毒副反应及低血糖事件，所以糖尿病肾病患者如何有效且安全的使用口服降糖药物至关重要。本文主要讨论各类口服降糖药物包括胰岛素促泌剂、非胰岛素促泌剂及新型口服降糖药物在糖尿病肾病中的应用。 |
| 关 键 词： | 糖尿病肾病 胰岛素促泌剂 非胰岛素促泌剂 新型口服降糖药物 |
| 收稿时间： | 2016-04-22 |
Progress of research on application of oral antidiabetic agents for patients with diabetic nephropathy |
|
| Niansong Wang,Li He,Dongsheng Cheng. Progress of research on application of oral antidiabetic agents for patients with diabetic nephropathy[J]. Chinese Journal of kidney disease investigation (Electronic Edition), 2016, 5(4): 155-158. DOI: 10.3877/cma.j.issn.2095-3216.2016.04.003 | |
| Authors: | Niansong Wang Li He Dongsheng Cheng |
| Affiliation: | 1. Department of Nephrology, Sixth People′s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200233, China |
| Abstract: | Diabetic nephropathy (DN) is one of the most common causes for end-stage renal disease (ESRD) in the world. Intensive glucose control is effective in decreasing the incidence and progression of DN. As the renal function reduces, accumulation of hypoglycemic drugs can occur in the patients, which increases adverse reactions of the drugs as well as hypoglycemia events. This article mainly discussed the application of oral hypoglycemic drugs used for DN, including insulin secretagogues, non-insulin secretagogues, and other new type of oral hypoglycemic drugs. |
| Keywords: | Diabetic nephropathy Insulin secretagogues Non-insulin secretagogues Oral hypoglycemic drugs new type |
| 点击此处可从《中华肾病研究电子杂志》浏览原始摘要信息 | |
| 点击此处可从《中华肾病研究电子杂志》下载全文 | |